January 14, 2021
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory scienceSIGN UP ⋅   SHARE
Europe
Swissmedic, Switzerland's drug regulator, has approved Moderna's COVID-19 vaccine, the second vaccine authorized for emergency use after the Pfizer/BioNTech vaccine. The approval will allow for the delivery of up to 1.5 million doses from both companies through February.
Full Story: Reuters (1/12) 
LinkedIn Twitter Facebook Email
AstraZeneca and partner Oxford University are seeking conditional marketing authorization for their COVID-19 vaccine, and the European Medicines Agency is about to initiate an accelerated review of its application. An opinion on the CMA could be issued by the agency by Jan. 29.
Full Story: PMLive (UK) (1/12) 
LinkedIn Twitter Facebook Email
Summit: How a Crisis Enabled Clinical Innovation
Life science companies have been forced to pivot to a digital-first environment and under intense pressure deliver diagnostics, vaccines and therapeutic solutions at unprecedented speed. Join our panel of experts on January 28, 2021 at 2PM ET to discuss how the regulatory environment was affected by the pandemic and predictions for the future of R&D. Register now.
ADVERTISEMENT
Asia Pacific
The Serum Institute of India will sell three million doses of AstraZeneca's COVID-19 vaccine to Bangladesh's Beximco Pharmaceuticals to be used on the private market. The vaccine could be delivered as soon as next month, according to a Beximco official.
Full Story: Reuters (1/12) 
LinkedIn Twitter Facebook Email
North America
Merck's application for V114, its 15-valent pneumococcal conjugate vaccine, was granted priority review status by the FDA, according to a company announcement. Merck said a decision on V114 is expected from the FDA by July 18.
Full Story: Healio (free registration) (1/12) 
LinkedIn Twitter Facebook Email
Eli Lilly and Co. reported mid-stage trial data showing that individuals with mild to moderate Alzheimer's disease who took its monoclonal antibody drug donanemab had 32% slower cognitive decline rate compared with those who were given placebo. Donanemab treatment also correlated with removal and persistent absence of amyloid plaques after six to 12 months, according to Eli Lilly Chief Scientific Officer Dr. Daniel Skovronsky.
Full Story: The New York Times (1/11) 
LinkedIn Twitter Facebook Email
Sponsored content from The Wall Street Journal
Free to read exclusively for SmartBrief readers
Latin America
Researchers say clinical trials in Brazil shows a COVID-19 vaccine under development by China's Sinovac Biotech was only 50.4% effective. The vaccine is one of two recommended by Brazilian officials, but efficacy rate may not be high enough for regulatory approval.
Full Story: Reuters (1/12) 
LinkedIn Twitter Facebook Email
Global
Recruiting volunteers for placebo-controlled clinical trials of next-generation COVID-19 vaccines has been rendered nearly impossible by the regulatory approval of several vaccines, and some volunteers in ongoing trials have already asked to drop out. Researchers are designing other ways to prove efficacy, such as by splitting cohorts so that twice as many participants receive the vaccine as the placebo, using an approved vaccine as the control or measuring immunity biomarkers to judge efficacy, but all have drawbacks.
Full Story: Nature (free content) (1/8) 
LinkedIn Twitter Facebook Email
Gilead Sciences CEO Daniel O'Day said the company is testing remdesivir to find out if it is effective in treating new variants of the novel coronavirus discovered in South Africa and the UK. "Remdesivir works at the source in the cell where the virus replicates, and what we know is in these new variants, that part of the cell is not changing at all in fact. So, we fully expect remdesivir to be effective against these new strains, " O'Day said.
Full Story: CNBC (1/11) 
LinkedIn Twitter Facebook Email
DIA News
The life sciences industry depends on timely and critical access to information, and you can gain fast, insightful, easy-to-acquire knowledge for quick decision-making through DIA NOW. DIA NOW is your one-stop for up-to-the-minute global life science trends, breaking news, and analysis -- coming to you on-demand, whenever you want, on any device. That's thousands of content items, resources, videos, and insights, continually refreshed for easy search, access, and use.

With more than 50 years of experience as the world's provider of the largest global, neutral stage for life science professionals to join together and address healthcare challenges, we invite you to join us in the digital realm and stay ahead of the life science conversations of today. Get started with your one-month free trial today!
LinkedIn Twitter Facebook Email
Expand your current skill set and further your career with DIA virtual events in Spring and Summer 2021. DIA events help professionals to stay on top of policy changes, best practices, and updated guidances through interactive workshops, engaging sessions, and networking event -- now held on your device anywhere in the world. Check out our upcoming, can't-miss conferences and trainings for healthcare and life sciences professionals to take yourself to the next level: 
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
Sharing DIA Global SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/dia/?referrerId=eSriBJbAIQ
Take a stand. Be known for your courage and confidence.
Indra Nooyi, business executive
LinkedIn Twitter Facebook Email
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004